| 词条 | Lennox–Gastaut syndrome |
| 释义 |
| name = Lennox–Gastaut syndrome | synonyms = | field = Neurology | symptoms = | complications = | onset = | duration = | types = | causes = | risks = | diagnosis = | differential = | prevention = | treatment = | medication = | prognosis = | frequency = | deaths = }}Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG). Typically, it presents in children aged 3–5 years and can persist into adulthood.[1][2] It has been associated with several gene mutations, perinatal insults, congenital infections, brain tumors/malformations, and genetic disorders such as tuberous sclerosis and West syndrome. The prognosis for LGS is poor with a 5% mortality in childhood and persistent seizures into adulthood (80%–90%).[3] LGS was named for neurologists William G. Lennox (Boston, USA) and Henri Gastaut (Marseille, France).[4] The international LGS Awareness Day is on November 1.[5] {{TOC limit}}Signs and symptomsThe symptoms vary and progress with age. The symptoms are characterized by a triad of seizures, cognitive dysfunction, and EEG findings. The triad may not fully emerge until 1–2 years after first seizure episode. SeizuresThe peak age of onset of seizures is typically between 3 and 5 years of age.[6] The mainstay symptoms is seizures that are frequent – occurring daily – and difficult to treat with antiseizure medications. An estimated 30% of patients with infantile spasms (West syndrome) have been reported to progress to LGS.[6][7] The seizures are most commonly tonic seizures. They occur most frequently during non-REM sleep (90%). The seizures initially last only a few seconds and are activated by sleep. The presentation can be subtle. They present often as tonic eyelid opening with some changes in breathing coupled with pupillary dilation, urinary incontinence, increased heart rate, and flushing can occur Nonconvulsive status epilepticus occurs in about 50% of patients. The seizures can cause sudden falling often leading to injury. These "drop attacks" are typically first manifestation of LGS. These drop attacks are characterized by single, generalized monoclonic jerk that precedes tonic contraction of axial muscles. EEG findingsFindings that strongly suggest LGS include consistent slow spike-wave (< 3 hertz [Hz]) on awake EEG. The complexes typically consist of a spike (duration < 70 milliseconds) or a sharp wave (70-200 milliseconds), followed first by a positive deep trough, then a negative wave (350-400 milliseconds). Not every wave is preceded by a spike. Bursts increase and decrease without clear onset and offset. Slow spike waves may occur during seizure or between seizures, or may occur in absence of any observable clinical changes which helps distinguish pattern from extended 3-Hz spike-wave discharges. Ocular abnormalityOcular abnormalities affect around 90% of children. They can present as refractive error, strabismus, cortical visual impairment, and premature retinopathy.[8] CausesThe disease pathophysiology is mostly unknown, but some evidence implicates cortical hyperexcitability occurring at critical periods of brain development. There are two types of LGS: idiopathic and secondary. Idiopathic is unknown origin. Secondary is when an identifiable underlying pathology is responsible. The most common type of LGS (70–78%) is secondary.[10] These patients tend to have a worse prognosis than those with idiopathic LGS.[11] In up to one-third of cases no cause can be found.[11] Brain injuryLennox Gastaut most often occurs secondary to brain damage. The brain damage can occur from perinatal insults, encephalitis, meningitis, tumor, and brain malformation. Genetic mutationsOther identified disorders include genetic disorders such as tuberous sclerosis and inherited deficiency of methylene tetrahydrofolate reductase. Some of these cases once thought to be of unknown cause may have definitive etiology by modern genetic testing.[11] Progress in genome and exome sequencing is revealing that some individuals diagnosed with Lennox Gastaut Syndrome have de novo mutations in a variety of genes, including CHD2, GABRB3, ALG13 and SCN2A[9][10] The Epi4K study consortium (2013) observed de novo mutations in at least 15% of a study cohort of 165 patients with LGS and infantile spasms using whole exome sequencing.[11] A 2013 study found a high frequency of rare copy-number variation (CNV's) in adult patients with LGS or LGS-like epilepsy[12] DiagnosisThe diagnosis of LGS should be suspected in children less than 8 years old with seizures of multiple types that cannot be treated with antiseizure medications. Because of high risk of irreversible brain damage in early stages of syndrome (particularly in infants and young children), early diagnosis is essential. It may take 1–2 years after first initial seizure for all criteria for diagnosis to emerge, so LGS should be considered if there are suggestive signs and symptoms without presence of complete triad. To confirm diagnosis, awake and asleep EEG and magnetic resonance imaging (MRI) are performed. MRI is used to detect focal brain lesions. Ruling out other diagnosisCertain diagnosis must be ruled out before diagnosing LGS. These diagnosis are:
LGS is more easily distinguished from LGS by seizure type after the syndrome has progressed. Doose syndrome has more myoclonic seizures and LGS has more tonic seizures. The Doose syndromes is less likely to have cognitive disabilities. The Dravet syndrome has a strong family history of epilepsy, unlike LGS. Also, many children with Dravet syndrome have seizures triggered by light. Pseudo-Lennox–Gastaut syndrome can be distinguished from LGS because pseudo-LGS has different spike-and-wave patterns on EEG. TreatmentThere are several treatment options, including medications, surgery, and diet. MedicationsIn most patients with LGS, the treatment does not end seizure recurrence. The goals of treatment are to lower frequency and severity of seizures to greatest extent possible. The appropriate treatment varies depending on individual.[13] The treatments for LGS has evolved over the years. Various treatments have been shown to have some degree of efficacy. In 1997-1999, lamotrigine was found to be effective and approved by the Food and Drug Administration and Health Canada.[14][15][16] In 1999, topiramate trials showed that topiramate decreased seizure occurrence by more than 50%.[17][18] Felbamate is the treatment of last resort in the event that everything else fails,[19] and was found to be superior to placebo in controlling treatment resistant partial seizures and atonic seizures.[20][21] However, it has been known to cause aplastic anemia and liver toxicity.[22]First-line drugs
Second-line drugs
Adjuvant drugs
SurgeryIn the past, LGS patients were not eligible for surgery, as the medical community thought the LGS involved the whole brain as a generalized epilepsy in all cases. Since 2010, this assumption has been challenged.[24] Two studies on LGS patients series who underwent curative surgery in Korea[25] and China,[26] showed very good results, up to seizure freedom for 80% of these patients below 5 years old, and 40% above 5 years old. Like all epilepsy curative surgeries, seizures may recur in the years following surgery, but surgery allows the child to have better brain development during the seizure free period. There are several procedures that have shown efficacy:
Diet{{main|Ketogenic diet}}A ketogenic diet is a diet that causes ketosis, a state in which there is an increased amount of ketones in the body. Adopting and maintaining rigid diet may be difficult for some families. Short-term ketogenic diet might be associated with nonsignificant decreases in frequency of parent-reported seizures in children with LGS.[27] A case series study showed 50% seizure reduction reported in almost half of children with LGS after 1 year of ketogenic diet. However, the strength of the study is challenged because it represents reports rather than scientific analysis of the clinical outcomes such as in a randomized controlled trial.[28] PrognosisThe mortality rate ranges from 3–7% in a mean follow up period of 8.5 to 9.7 years. Death is often related to accidents.[29] EpidemiologyLGS is seen in approximately 4% of children with epilepsy, and is more common in males than in females.[10] Usual onset is between the ages of three and five.[30] Children can have no neurological problems prior diagnosis, or have other forms of epilepsy. West syndrome is diagnosed in 20% of patients before it evolves into LGS at about 2 years old.[31] FinlandAccording to a 1997 community-based retrospective study in the Helsinki metropolitan area and the province of Uusimaa, the annual incidence of Lennox–Gastaut was 2 in 100,000 (0.002%) from 1975 to 1985.[32] United States0.026% of all children in the Atlanta, Georgia metropolitan area were estimated to have LGS in 1997, which was defined as, "onset of multiple seizure types before age 11 years, with at least one seizure type resulting in falls, and an EEG demonstrating slow spike-wave complexes (<2.5 Hz)." The study concluded that LGS accounts for 4% of childhood epilepsies.[33] ResearchVigabatrin was found by Feucht et al. to be an effective add-on in patients whose seizures were not satisfactorily controlled by valproate. Out of 20 children, only 1 experienced a serious side effect (dyskinesia).[34]Zonisamide showed promise in an overview of controlled and uncontrolled trials conducted in Japan.[35] However, in a physician survey conducted December 2004, only 28% of Lennox–Gastaut and West syndrome patients improved on zonisamide.[36]One yet to be published study from 2017 supported the use of cannabidiol.[37] Another article published in the New England Journal of Medicine has also shown a significant reduction of seizures of patients taking 10 and 20 mg/kg a day compared to placebo. [36] References1. ^{{Cite journal|title = Lennox–Gastaut syndrome (childhood epileptic encephalopathy)|journal = Journal of Clinical Neurophysiology|date = 2003-12-01|issn = 0736-0258|pmid = 14734932|pages = 426–441|volume = 20|issue = 6|first = Omkar N.|last = Markand|doi=10.1097/00004691-200311000-00005}} 2. ^{{Cite journal|title = Conceptualizing Lennox–Gastaut syndrome as a secondary network epilepsy|journal = Epilepsy|date = 2014-01-01|pmc = 4214194|pmid = 25400619|pages = 225|volume = 5|doi = 10.3389/fneur.2014.00225|first = John S.|last = Archer|first2 = Aaron E. L.|last2 = Warren|first3 = Graeme D.|last3 = Jackson|first4 = David F.|last4 = Abbott}} 3. ^{{Cite journal|last=Asadi-Pooya|first=Ali A.|date=March 2018|title=Lennox-Gastaut syndrome: a comprehensive review|journal=Neurological Sciences|volume=39|issue=3|pages=403–414|doi=10.1007/s10072-017-3188-y|issn=1590-3478|pmid=29124439}} 4. ^Dravet, C., & Roger, J. (1996). Henri Gastaut 1915-1995. Epilepsia, 37(4), 410–415. https://doi.org/10.1111/j.1528-1157.1996.tb00580.x 5. ^http://www.lgsfoundation.org 6. ^Albert P. Aldenkamp, Fritz E. Dreifuss, W. Renier, T.P.B.M. Suurmeijer, Epilepsy in Children and Adolescents. Pg. 51 7. ^Ohtahara S, Yamatogi Y, Ohtsukd Y, Oka E, lshida T. Prognosis of West syndrome with special reference to Lennox syndrome: a developmental study. In: Wada JA, Penry JK, eds. Advunces in epileptology: The Xth EpilepsyInternational Symposium. New York: Raven Press, 1980: 149–54 8. ^{{cite journal |vauthors=Kim BH, Yu YS, Kim SJ |title=Ophthalmologic Features of Lennox-Gastaut Syndrome |journal=Korean J Ophthalmol |volume=31 |issue=3 |pages=263–267 |date=June 2017 |pmid=28471101 |pmc=5469930 |doi=10.3341/kjo.2015.0161 |url=}} 9. ^{{cite journal|vauthors=Lund C, Brodtkorb E, Øye AM, Røsby O, Selmer KK|year=2014|title=CHD2 mutations in Lennox–Gastaut syndrome|journal=Epilepsy Behav.|volume=33|pages=18–21|doi=10.1016/j.yebeh.2014.02.005|pmc=|pmid=24614520}} 10. ^{{cite journal|vauthors=LCapelli LP, Krepischi AC, Gurgel-Giannetti J, Mendes MF, Rodrigues T, Varela MC, Koiffmann CP, Rosenberg C|year=2012|title=Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency|journal=Eur J Med Genet.|volume=55|issue=2|pages=132–134|doi=10.1016/j.ejmg.2011.10.004|pmc=|pmid=22178256}} 11. ^{{Cite journal|vauthors=Allen AS, Berkovic SF, Cossette P, etal|date=2013-09-12|title=De novo mutations in the classic epileptic encephalopathies|journal=Nature|volume=501|issue=7466|pages=217–221|doi=10.1038/nature12439|issn=0028-0836|pmc=3773011|pmid=23934111}} 12. ^{{Cite journal|last=Lund|first=Caroline|last2=Brodtkorb|first2=Eylert|last3=Røsby|first3=Oddveig|last4=Rødningen|first4=Olaug Kristin|last5=Selmer|first5=Kaja Kristine|date=2013-07-01|title=Copy number variants in adult patients with Lennox–Gastaut syndrome features|journal=Epilepsy Research|volume=105|issue=1–2|pages=110–117|doi=10.1016/j.eplepsyres.2013.01.009|issn=1872-6844|pmid=23415449}} 13. ^{{cite journal|last1=Hancock|first1=EC|last2=Cross|first2=JH|date=28 February 2013|title=Treatment of Lennox–Gastaut syndrome.|journal=The Cochrane Database of Systematic Reviews|issue=2|pages=CD003277|doi=10.1002/14651858.CD003277.pub3|pmid=23450537}} 14. ^{{cite journal|last1=Motte|first1=J|last2=Trevathan|first2=E|last3=Arvidsson|first3=JF|last4=Barrera|first4=MN|last5=Mullens|first5=EL|last6=Manasco|first6=P|year=1997|title=Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group|journal=The New England Journal of Medicine|volume=337|issue=25|pages=1807–12|doi=10.1056/NEJM199712183372504|pmid=9400037}} 15. ^{{cite web|url=http://epilepsyontario.org/client/EO/EOWeb.nsf/web/Lamotrigine+Approved+in+Canada+for+Lennox-Gastaut+Syndrome|title=Lamotrigine Approved in Canada for Lennox–Gastaut Syndrome|author=Epilepsy Ontario|year=1999|work='Sharing' News|accessdate=13 November 2005}} 16. ^{{cite web|url=http://www.fda.gov/cder/foi/nda/98/020241s003.htm|title=Final Printed Labeling—Part 1|author=Glaxo Wellcome Inc|year=1998|work=Lamictal Tablets & Chewable Dispersible Tablets (Lamotrigine) Drug Approval Page|publisher=United States Food and Drug Administration Center for Drug Evaluation and Research|archiveurl=https://web.archive.org/web/20050429104322/http://www.fda.gov/CDER/foi/nda/98/020241s003.htm|archivedate=April 29, 2005|deadurl=yes|accessdate=13 November 2005}} 17. ^{{cite journal|author=Sachdeo, R. C.|last2=Glauser|first2=TA|last3=Ritter|first3=F|last4=Reife|first4=R|last5=Lim|first5=P|last6=Pledger|first6=G|year=1999|title=A double-blind, randomized trial of topiramate in Lennox–Gastaut syndrome|url=http://www.neurology.org/cgi/content/abstract/52/9/1882|journal=Neurology|volume=52|issue=9|pages=1882–7|doi=10.1212/wnl.52.9.1882|pmid=10371538}} 18. ^{{cite journal|last1=Alva-Moncayo|first1=E|last2=Ruiz-Ruiz|first2=A|year=2003|title=Utilidad del topiramato como terapia añadida a esquemas convencionales para el síndrome de Lennox–Gastaut|trans-title=The value of topiramate used with conventional schemes as an adjunctive therapy in the treatment of Lennox–Gastaut syndrome|url=http://www.revneurol.com/sec/resumen.php?or=pubmed&id=2002014|journal=Revista de Neurologia|language=Spanish|volume=36|issue=5|pages=453–7|pmid=12640599}} 19. ^{{cite web|url=http://www.rxlist.com/cgi/generic/felbamate_ids.htm|title=Felbatol (felbamate)|page=3|archiveurl=https://web.archive.org/web/20071109125217/http://www.rxlist.com/cgi/generic/felbamate_ids.htm|archivedate=2007-11-09|deadurl=yes|accessdate=2007-09-19|df=}} 20. ^{{cite journal|last1=The Felbamate Study Group In Lennox–Gastaut Syndrome|year=1993|title=Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox–Gastaut Syndrome|journal=The New England Journal of Medicine|volume=328|issue=1|pages=29–33|doi=10.1056/NEJM199301073280105|pmid=8347179}} 21. ^{{cite journal|last1=Devinsky|first1=O|last2=Faught|first2=RE|last3=Wilder|first3=BJ|last4=Kanner|first4=AM|last5=Kamin|first5=M|last6=Kramer|first6=LD|last7=Rosenberg|first7=A|year=1995|title=Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures|journal=Epilepsy Research|volume=20|issue=3|pages=241–6|doi=10.1016/0920-1211(94)00084-A|pmid=7796796}} 22. ^{{cite journal|last1=O'neil|first1=MG|last2=Perdun|first2=CS|last3=Wilson|first3=MB|last4=Mcgown|first4=ST|last5=Patel|first5=S|year=1996|title=Felbamate-associated fatal acute hepatic necrosis|journal=Neurology|volume=46|issue=5|pages=1457–9|doi=10.1212/wnl.46.5.1457|pmid=8628501}} 23. ^{{cite journal|vauthors=Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW|date=August 2007|title=Rufinamide: a new anti-epileptic medication|journal=Expert Opin Pharmacother|volume=8|issue=12|pages=1931–40|doi=10.1517/14656566.8.12.1931|pmid=17696794}} 24. ^{{cite journal|last=Douglass|first=LM|year=2014|title=Surgical options for patients with Lennox–Gastaut syndrome|journal=Epilepsia|volume=55|pages=21–28|doi=10.1111/epi.12742|pmid=25284034}} 25. ^{{cite journal|last=Lee|first=Yun Jin|year=2010|title=Resective pediatric epilepsy surgery in Lennox–Gastaut syndrome|url=http://pediatrics.aappublications.org/content/125/1/e58|journal=Pediatrics|volume=125|issue=1|pages=e58–e66|via=|doi=10.1542/peds.2009-0566|pmid=20008422}} 26. ^{{cite journal|last=Liu|first=SY|year=2012|title=Surgical treatment of patients with Lennox–Gastaut syndrome phenotype|journal=The Scientific World Journal|volume=2012|page=614263|doi=10.1100/2012/614263|pmc=3353538|pmid=22629163|via=}} 27. ^{{Cite journal|last=Freeman|first=John M.|date=February 2009|title=Seizures, EEG events, and the ketogenic diet|journal=Epilepsia|volume=50|issue=2|pages=329–330|doi=10.1111/j.1528-1167.2008.01757.x|issn=1528-1167|pmid=19215282}} 28. ^{{Cite journal|last=Cross|first=J. Helen|date=May 2012|title=The ketogenic diet in the treatment of Lennox-Gastaut syndrome|journal=Developmental Medicine and Child Neurology|volume=54|issue=5|pages=394–395|doi=10.1111/j.1469-8749.2012.04276.x|issn=1469-8749|pmid=22443688}} 29. ^{{cite web |author1=Glauser, Tracy A. |author2=Morita, Diego A. |year=2002 |title=Introduction |url=http://www.emedicine.com/neuro/topic186.htm |work=Lennox–Gastaut Syndrome |publisher=eMedicine.com, Inc. |accessdate=8 July 2005}} 30. ^1 {{Cite journal|last=Bourgeois|first=Blaise F. D.|last2=Douglass|first2=Laurie M.|last3=Sankar|first3=Raman|date=2014-09-01|title=Lennox–Gastaut syndrome: a consensus approach to differential diagnosis|journal=Epilepsia|volume=55 Suppl 4|pages=4–9|doi=10.1111/epi.12567|issn=1528-1167|pmid=25284032}} 31. ^1 2 3 {{cite journal | url=http://www.ijpbs.net/issue-3/82.pdf | title=Pharmacological Management of Lennox–Gastaut Syndrome a Difficult to Treat Form of Childhood-Onset Epilepsy: An Overview | author=Tyagi, Satyanand| journal=International Journal of Pharma and Bio Sciences |date=Jul–Sep 2010 | volume=1 | issue=3 | pages=1–6|display-authors=etal}} 32. ^{{cite journal |pmid=9184597 |doi=10.1111/j.1528-1157.1997.tb01136.x |year=1997 |last1=Heiskala |first1=H |title=Community-based study of Lennox–Gastaut syndrome |volume=38 |issue=5 |pages=526–31 |journal=Epilepsia}} 33. ^1 2 {{cite journal |pmid=9578523 |doi=10.1111/j.1528-1157.1997.tb00065.x |year=1997 |last1=Trevathan |first1=E |last2=Murphy |first2=CC |last3=Yeargin-Allsopp |first3=M |title=Prevalence and descriptive epidemiology of Lennox–Gastaut syndrome among Atlanta children |volume=38 |issue=12 |pages=1283–8 |journal=Epilepsia}} 34. ^{{cite journal |pmid=7925171 |doi=10.1111/j.1528-1157.1994.tb02544.x |year=1994 |last1=Feucht |first1=M |last2=Brantner-Inthaler |first2=S |title=Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox–Gastaut syndrome: an open study |volume=35 |issue=5 |pages=993–8 |journal=Epilepsia}} 35. ^{{cite journal |pmid=15511680 |doi=10.1016/j.seizure.2004.04.018 |year=2004 |last1=Yagi |first1=K |title=Overview of Japanese experience-controlled and uncontrolled trials |volume=13 Suppl 1 |pages=S11–5; discussion S16 |journal=Seizure : The Journal of the British Epilepsy Association}} 36. ^{{cite journal |doi=10.1016/j.seizure.2004.04.021 |pmid=15511689 |year=2004 |last1=Yamauchi |first1=T |last2=Aikawa |first2=H |title=Efficacy of zonisamide: our experience |volume=13 Suppl 1 |pages=S41–8; discussion S49 |journal=Seizure : The Journal of the British Epilepsy Association}} 37. ^{{cite web|title=Lennox-Gastaut Syndrome: Cannabidiol Treatment {{!}} Neurology Times|url=http://www.neurologytimes.com/aan-2017/lennox-gastaut-syndrome-cannabidiol-treatment|website=www.neurologytimes.com|accessdate=27 April 2017|language=en|date=23 April 2017}} External links{{Medical resources| ICD10 = {{ICD10|G|40|4|g|40}} | ICD9 = {{ICD9|345.0}} | eMedicineSubj = neuro | eMedicineTopic = 186 | DiseasesDB = 29493 | Orphanet = 2382 | LGS Foundation }}{{Seizures and epilepsy}}{{DEFAULTSORT:Lennox-Gastaut Syndrome}} 6 : Neurological disorders|Epilepsy types|Syndromes affecting the nervous system|Medical triads|Rare syndromes|Disorders causing seizures |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。